Neuroprotection for ischemic stroke: two decades of success and failure.
Neuroprotection for ischemic stroke: two decades of success and failure.
复制标题
DOI：
10.1602/neurorx.1.1.36
复制
发表时间：
2004-01-01
期刊：
影响因子：
--
通讯作者：
Zivin, Justin A
中科院分区：
文献类型：
--
作者：
Cheng, Yu Dennis;Al-Khoury, Lama;Zivin, Justin A
阿替普酶（rt-PA）是首个成功开发用于急性卒中治疗的疗法。rt-PA的成功刺激了急性中风治疗新途径的开发。在过去的二十年里，神经保护疗法受到了极大的关注。最初的临床前研究表明，许多药物在动物模型中对治疗急性中风有效;然而，随后的临床试验令人沮丧，没有一种药物被证明是有效的。临床前和临床试验的各种结果一直是许多讨论的主题。在这篇文章中，我们回顾了一些关键的神经保护试验及其失败的可能原因。通过识别临床前研究和临床试验之间的差异，我们可能能够为未来的有效试验制定指导方针。
Alteplase (rt-PA) is the first therapy successfully developed for acute stroke therapy. The success of rt-PA spurred development of new avenues for acute stroke management. For the last two decades, a great deal of attention has been paid to neuroprotective therapies. Initial preclinical studies demonstrated numerous drugs are effective for treating acute stroke in animal models; however, subsequent clinical trials have been frustrating, and none of the agents has proven effective. The various outcomes of preclinical and clinical trials have been the subject of much discussion. In this article, we review some key neuroprotective trials and the possible reasons for their failures. By identifying the discrepancies between preclinical studies and clinical trials, we may be able to set guidelines for future effective trials.